Baird analyst Jack Allen lowered the firm’s price target on Vor Bio to $22 from $38 and keeps an Outperform rating on the shares. The analyst said fundamentally we continue to have high conviction in Vor’s scientific thesis; however, given the macroeconomic conditions we are reducing our price target to reflect the increased risk of dilution.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VOR:
- Vor Bio reports Q4 EPS (53c), consensus (60c)
- Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
- Vor Bio to Participate in Upcoming Investor Conferences
- First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
- Vor Bio presents clinical data from VBP101 Phase 1/2a study of trem-cel
